A5095041744- Calcium signaling and nucleotide metabolism
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
- Breast Cancer Treatment Studies
- Adenosine and Purinergic Signaling
- Metabolism, Diabetes, and Cancer
- Sarcoma Diagnosis and Treatment
- Synthesis and Biological Evaluation
- PI3K/AKT/mTOR signaling in cancer
- Cancer Immunotherapy and Biomarkers
- Cell Adhesion Molecules Research
- HER2/EGFR in Cancer Research
- Metastasis and carcinoma case studies
- Immune cells in cancer
- Cancer therapeutics and mechanisms
- Gastrointestinal Tumor Research and Treatment
- Estrogen and related hormone effects
- Advanced Breast Cancer Therapies
- Peptidase Inhibition and Analysis
- Immunotherapy and Immune Responses
The University of Texas MD Anderson Cancer Center
2024-2025
Abstract Triple-negative breast cancer (TNBC) is a highly metastatic subtype of cancer. The epithelial-to-mesenchymal transition nonbinary process in the cascade that generates tumor cells with both epithelial and mesenchymal traits known as hybrid EM cells. Recent studies have elucidated enhanced potential cancers featuring phenotype, highlighting need to uncover molecular drivers targetable vulnerabilities state. Here, we discovered tumors are enriched CD38, an immunosuppressive molecule...
<div>Abstract<p>Triple-negative breast cancer (TNBC) is a highly metastatic subtype of cancer. The epithelial-to-mesenchymal transition nonbinary process in the cascade that generates tumor cells with both epithelial and mesenchymal traits known as hybrid EM cells. Recent studies have elucidated enhanced potential cancers featuring phenotype, highlighting need to uncover molecular drivers targetable vulnerabilities state. Here, we discovered tumors are enriched CD38, an...
<p>Supplementary data, tables and legends</p>
Abstract Background: TROP2, a transmembrane glycoprotein implicated in tumor progression and metastasis, exhibits variable expression across breast cancer subtypes. The classic variant of invasive lobular carcinoma (ILC-C) the pleomorphic (ILC-P) display distinct morphological biological characteristics. This study aims to investigate differences TROP2 between ILC-C ILC-P, enhancing our understanding its potential as biomarker for aggressive Methods: protein was evaluated 14 samples (8 6...
The Wnt receptor ROR1 has generated increased interest as a cancer therapeutic target. Research on several approaches involving this is ongoing; however, tissue expression remains understudied. We performed an immunohistochemistry analysis of protein in large cohort multiple tumor and histologic types. analyzed 12 anonymized multi-tumor microarrays (TMAs), including mesothelioma, esophageal upper gastrointestinal carcinomas, uterine endometrioid carcinoma, among other Additionally, we...
Breast cancer is the most common among women. Metaplastic breast carcinoma (MpBC) a rare, heterogeneous group of invasive carcinomas, which are classified as predominantly triple-negative carcinomas (TNBCs; HR-negative/HER2-negative). Histologically, MpBC into six subtypes. Two these considered low-grade and others high-grade. MpBCs seem to be more aggressive, less responsive neoadjuvant chemotherapy, have higher rates chemoresistance than other TNBCs. lower survival rate expected for...
<h3>Background</h3> Hormone receptor-positive (HR<sup>+</sup>) HER2<sup>-</sup>, HER2 enriched (HER2<sup>+</sup>), and triple negative breast carcinoma (TNBC) are different molecular intrinsic subtypes of cancer (BC). While each subtype has distinct tumor immunogenicity features, how this translates into the circulating immune composition is unknown. This study explored potential differences in system between metastatic HR<sup>+</sup>HER2<sup>-</sup>, HER2<sup>+</sup> TNBC patients....
Abstract Emerging evidence suggests that cancer cells can mimic features of immune during oncogenic transformation to drive disease progression. We assessed the occurrence immunological markers in breast determine their expression pattern. initially analyzed 18 protein (CCR4, CCR6, CCR7, CD11, CD123, CD14, CD16, CD19, CD24, CD25, CD27, CD3, CD38, CD4, CD45, CD56, CD8 and CXCR3) expressed on surface 28 cell lines using mass spectrometry. CD14 tumor its association with clinical outcomes was...